<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02198417</url>
  </required_header>
  <id_info>
    <org_study_id>2014P000911</org_study_id>
    <secondary_id>R01HD065029</secondary_id>
    <nct_id>NCT02198417</nct_id>
  </id_info>
  <brief_title>Metformin Treatment in Polycystic Ovary Syndrome (PCOS)</brief_title>
  <official_title>Effects of Metformin on Mitochondrial Function in Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PCOS occurs when a woman does not release an egg regularly each month, causing her periods to&#xD;
      be irregular. Women with PCOS can also have increased hair growth on the face and body, acne,&#xD;
      head balding, infertility, pre-diabetes, and diabetes. PCOS is commonly treated with oral&#xD;
      contraceptive pills (also known as the birth control pills). Sometimes, a medication called&#xD;
      metformin is also used to treat PCOS, especially if a woman has evidence of insulin&#xD;
      resistance or if fertility is desired. Unfortunately, metformin works in only some women with&#xD;
      PCOS. The mechanism through which metformin works in PCOS is not clear and it difficult to&#xD;
      predict who will benefit from metformin treatment and who will not.&#xD;
&#xD;
      The investigators are doing this research study to look at how the medication metformin&#xD;
      affects the cells in the body of patients with PCOS. Specifically, the investigators will&#xD;
      look at how metformin affects the mitochondria. Mitochondria are the part of cells that&#xD;
      produce fuel (energy) for other cells and play a role in metabolism. The investigators would&#xD;
      like to see whether there is a relationship between mitochondrial activity and symptoms of&#xD;
      polycystic ovary syndrome (PCOS) before and after treatment with metformin. They would also&#xD;
      like to study whether genes affect the response to metformin in women with PCOS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women who are eligible to enroll in this study will be treated with the medication metformin&#xD;
      for 12 weeks. Before and after treatment with metformin, the following will be assessed:&#xD;
&#xD;
        -  Weight, blood pressure, waist circumference&#xD;
&#xD;
        -  Lipids (cholesterol)&#xD;
&#xD;
        -  Hormone levels (including testosterone and other androgens)&#xD;
&#xD;
        -  IV glucose tolerance test (to assess for early evidence of insulin resistance)&#xD;
&#xD;
        -  Effect of metformin on muscle mitochondria (this will involve one MRI scan and one&#xD;
           muscle biopsy each before and after treatment with metformin)&#xD;
&#xD;
      Ovulation will be closely monitored at least twice a month with pelvic ultrasounds and blood&#xD;
      tests for estrogen and progesterone levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle Metabolism/Mitochondrial Function</measure>
    <time_frame>3 months</time_frame>
    <description>The change in mitochondrial activity before and after metformin treatment will be analyzed in relationship to the clinical response to 3 months of metformin treatment (i.e., clinical response to metformin = changes in glucose metabolism, hormone levels, and ovulation response)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genetic risk variants affecting mitochondrial function/metabolism</measure>
    <time_frame>3 months</time_frame>
    <description>Blood will be analyzed for differences in genes between patients and its relationship to mitochondrial function.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin ER 1500 mg per day treatment for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin ER</intervention_name>
    <description>Treatment with metformin ER for 12 weeks</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Polycystic ovary syndrome&#xD;
&#xD;
          -  No hormonal or antidiabetic medications for 1 month&#xD;
&#xD;
          -  Good general health&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoker&#xD;
&#xD;
          -  Acute infection or chronic disease&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Pregnant or trying to get pregnant over next half year&#xD;
&#xD;
          -  Bleeding disorders&#xD;
&#xD;
          -  Any metal or foreign implants (e.g., aneurysm clips, ear implants, heart pacemakers or&#xD;
             defibrillators)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corrine Welt, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Pau CT, Keefe C, Duran J, Welt CK. Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study. J Clin Endocrinol Metab. 2014 May;99(5):1870-8. doi: 10.1210/jc.2013-4021. Epub 2014 Feb 25.</citation>
    <PMID>24606093</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 17, 2014</study_first_submitted>
  <study_first_submitted_qc>July 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2014</study_first_posted>
  <last_update_submitted>August 14, 2018</last_update_submitted>
  <last_update_submitted_qc>August 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Corrine Welt</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Polycystic Ovary Syndrome</keyword>
  <keyword>PCOS</keyword>
  <keyword>Acne</keyword>
  <keyword>Infertility</keyword>
  <keyword>Irregular menses</keyword>
  <keyword>Irregular period</keyword>
  <keyword>Mitochondria</keyword>
  <keyword>Metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

